Entrada Therapeutics annual operating expenses
2020
2021
2022
2023
2024
2025
Entrada Therapeutics Operating Expenses Growth & History (TRDA)
Entrada Therapeutics's operating expenses was $183.3M for fiscal 2025.
View full Entrada Therapeutics company overviewEntrada Therapeutics annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $183.3M | $19.5M | +11.94% |
| 2024 | 2024-12-31 | $163.8M | $31.6M | +23.90% |
| 2023 | 2023-12-31 | $132.2M | $34.9M | +35.92% |
| 2022 | 2022-12-31 | $97.2M | $46.1M | +90.21% |
| 2021 | 2021-12-31 | $51.1M | $24.5M | +91.72% |
| 2020 | 2020-12-31 | $26.7M | — | — |
Entrada Therapeutics quarterly operating expenses
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $45.9M | −$2.9M | −6.02% |
| Q1 2026 | 2026-03-31 | $43.2M | $830,000 | +1.96% |
| Q4 2025 | 2025-12-31 | $43.5M | $242,000 | +0.56% |
| Q3 2025 | 2025-09-30 | $48.7M | $7.4M | +18.04% |
| Q2 2025 | 2025-06-30 | $48.8M | $7.5M | +18.24% |
| Q1 2025 | 2025-03-31 | $42.3M | $4.3M | +11.42% |
| Q4 2024 | 2024-12-31 | $43.3M | $6.3M | +17.11% |
| Q3 2024 | 2024-09-30 | $41.2M | $11.5M | +38.71% |
| Q2 2024 | 2024-06-30 | $41.3M | $6.8M | +19.73% |
| Q1 2024 | 2024-03-31 | $38.0M | $7.0M | +22.45% |
| Q4 2023 | 2023-12-31 | $36.9M | $11.4M | +44.43% |
| Q3 2023 | 2023-09-30 | $29.7M | $3.8M | +14.60% |
| Q2 2023 | 2023-06-30 | $34.5M | $10.9M | +46.17% |
| Q1 2023 | 2023-03-31 | $31.0M | $8.9M | +40.13% |
| Q4 2022 | 2022-12-31 | $25.6M | $7.1M | +38.56% |
| Q3 2022 | 2022-09-30 | $25.9M | $11.6M | +80.56% |
| Q2 2022 | 2022-06-30 | $23.6M | $13.7M | +137.96% |
| Q1 2022 | 2022-03-31 | $22.2M | $13.8M | +163.92% |
| Q4 2021 | 2021-12-31 | $18.5M | — | — |
| Q3 2021 | 2021-09-30 | $14.4M | $7.4M | +105.99% |
| Q2 2021 | 2021-06-30 | $9.9M | — | — |
| Q1 2021 | 2021-03-31 | $8.4M | — | — |
| Q3 2020 | 2020-09-30 | $7.0M | — | — |
Entrada Therapeutics operating expenses trends
Over the last five fiscal years, Entrada Therapeutics's operating expenses increased from $26.7M to $183.3M, a change of $156.7M. The latest reported quarter, Q2 2026, shows $45.9M.
About the metric
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
Calculation and source
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Entrada Therapeutics source filings ↗